STARLITE 2: Phase 2 study of nivolumab plus 177lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab (177Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC).-MedSci.cn

STARLITE 2: Phase 2 study of nivolumab plus 177lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab (177Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC).

Feldman, DR; Motzer, RJ; Knezevic, A; Lee, CH; Voss, MH; Lyashchenko, SK; Park, H; Larson, SM; Pandit-Taskar, N

JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 ():

科室
- - 订阅+
  - 更多科室
工具
服务